Regeneron Pharmaceuticals Inc. buy HSBC Holdings plc
Start price
24.11.25
/
50%
€662.20
Target price
24.11.26
€221.52
Performance (%)
2.35%
Price
09:05
€676.80
Summary
This prediction is currently active. With a performance of 2.35%, the BUY prediction by HSBC_Holdings_plc for Regeneron Pharmaceuticals Inc. is trending in the right direction. Dividends of €0.94 are taken into consideration when calculating the performance. This prediction currently runs until 24.11.26. The prediction end date can be changed by HSBC_Holdings_plc at any time. HSBC_Holdings_plc has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.867% | 1.867% |
| iShares Core DAX® | -3.809% | -1.472% |
| iShares Nasdaq 100 | 0.487% | 2.215% |
| iShares Nikkei 225® | -4.418% | 4.971% |
| iShares S&P 500 | 0.251% | 1.225% |
Comments by HSBC_Holdings_plc for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at HSBC Holdings plc. They set a "buy" rating and a $255.00 price target on the stock.
Ratings data for REGN provided by MarketBeat